TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer
Само за регистроване кориснике
2010
Аутори
Ziauddin, M.F.Guo, Z.S.
O'Malley, M.E.
Austin, F.
Popović, Petar
Kavanagh, M.A.
Li, J.
Sathaiah, M.
Thirunavukarasu, P.
Fang, B.
Lee, Y.J.
Bartlett, D.L.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
We have explored a unique combination therapy for metastatic colorectal cancer. This strategy combines a potent and new oncolytic poxvirus expressing a membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or TNFSF10) and oxaliplatin (Ox) chemotherapy. We hypothesized that TRAIL expression would increase the efficacy of the oncolytic poxvirus, and that the therapeutic efficacy would be further enhanced by combination with chemotherapy. The cytotoxicity to cancer cells by Ox, oncolytic vaccinia virus (VV) and trail gene-armed VV alone or in combination was tested in vitro. The trail gene armed oncolytic VV-expressed high levels of TRAIL in infected cancer cells and had greater potency as a cytotoxic agent compared with the parent VV. Ox alone exerted concentration-dependent cytotoxicity. In vitro, the combination of the two agents applied at suboptimal concentrations for individual therapy displayed synergy in inducing cancer cells into enhanced levels of apoptos...is/necrosis. Western blot analyses were consistent with the notion that TRAIL induced cancer cell death mainly through apoptosis, whereas Ox and vJS6 induced cell death more through non-apoptotic death pathways. In two aggressive colorectal carcinomatosis models derived from human HCT116 and murine MC38 cells, the combination therapy displayed synergistic or additive antitumor activity and prolonged the survival of the tumor-bearing mice compared with either Ox chemotherapy or vvTRAIL-mediated oncolytic gene therapy alone. This combination strategy may provide a new avenue to treating peritoneal carcinomatosis and other types of metastases of colorectal cancer.
Кључне речи:
Chemotherapy / Colorectal cancer / Gene therapy / Vaccinia / VirotherapyИзвор:
Gene Therapy, 2010, 17, 4, 550-559Издавач:
- Nature
Финансирање / пројекти:
- The NIH R01 grant CA100415
- The Intramural Research Program of the NIH
- David C Koch Regional Therapy Cancer Center
DOI: 10.1038/gt.2010.5
ISSN: 1476-5462
PubMed: 20182517
WoS: 000276425800013
Scopus: 2-s2.0-77950859546
Институција/група
PharmacyTY - JOUR AU - Ziauddin, M.F. AU - Guo, Z.S. AU - O'Malley, M.E. AU - Austin, F. AU - Popović, Petar AU - Kavanagh, M.A. AU - Li, J. AU - Sathaiah, M. AU - Thirunavukarasu, P. AU - Fang, B. AU - Lee, Y.J. AU - Bartlett, D.L. PY - 2010 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5537 AB - We have explored a unique combination therapy for metastatic colorectal cancer. This strategy combines a potent and new oncolytic poxvirus expressing a membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or TNFSF10) and oxaliplatin (Ox) chemotherapy. We hypothesized that TRAIL expression would increase the efficacy of the oncolytic poxvirus, and that the therapeutic efficacy would be further enhanced by combination with chemotherapy. The cytotoxicity to cancer cells by Ox, oncolytic vaccinia virus (VV) and trail gene-armed VV alone or in combination was tested in vitro. The trail gene armed oncolytic VV-expressed high levels of TRAIL in infected cancer cells and had greater potency as a cytotoxic agent compared with the parent VV. Ox alone exerted concentration-dependent cytotoxicity. In vitro, the combination of the two agents applied at suboptimal concentrations for individual therapy displayed synergy in inducing cancer cells into enhanced levels of apoptosis/necrosis. Western blot analyses were consistent with the notion that TRAIL induced cancer cell death mainly through apoptosis, whereas Ox and vJS6 induced cell death more through non-apoptotic death pathways. In two aggressive colorectal carcinomatosis models derived from human HCT116 and murine MC38 cells, the combination therapy displayed synergistic or additive antitumor activity and prolonged the survival of the tumor-bearing mice compared with either Ox chemotherapy or vvTRAIL-mediated oncolytic gene therapy alone. This combination strategy may provide a new avenue to treating peritoneal carcinomatosis and other types of metastases of colorectal cancer. PB - Nature T2 - Gene Therapy T1 - TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer VL - 17 IS - 4 SP - 550 EP - 559 DO - 10.1038/gt.2010.5 ER -
@article{ author = "Ziauddin, M.F. and Guo, Z.S. and O'Malley, M.E. and Austin, F. and Popović, Petar and Kavanagh, M.A. and Li, J. and Sathaiah, M. and Thirunavukarasu, P. and Fang, B. and Lee, Y.J. and Bartlett, D.L.", year = "2010", abstract = "We have explored a unique combination therapy for metastatic colorectal cancer. This strategy combines a potent and new oncolytic poxvirus expressing a membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or TNFSF10) and oxaliplatin (Ox) chemotherapy. We hypothesized that TRAIL expression would increase the efficacy of the oncolytic poxvirus, and that the therapeutic efficacy would be further enhanced by combination with chemotherapy. The cytotoxicity to cancer cells by Ox, oncolytic vaccinia virus (VV) and trail gene-armed VV alone or in combination was tested in vitro. The trail gene armed oncolytic VV-expressed high levels of TRAIL in infected cancer cells and had greater potency as a cytotoxic agent compared with the parent VV. Ox alone exerted concentration-dependent cytotoxicity. In vitro, the combination of the two agents applied at suboptimal concentrations for individual therapy displayed synergy in inducing cancer cells into enhanced levels of apoptosis/necrosis. Western blot analyses were consistent with the notion that TRAIL induced cancer cell death mainly through apoptosis, whereas Ox and vJS6 induced cell death more through non-apoptotic death pathways. In two aggressive colorectal carcinomatosis models derived from human HCT116 and murine MC38 cells, the combination therapy displayed synergistic or additive antitumor activity and prolonged the survival of the tumor-bearing mice compared with either Ox chemotherapy or vvTRAIL-mediated oncolytic gene therapy alone. This combination strategy may provide a new avenue to treating peritoneal carcinomatosis and other types of metastases of colorectal cancer.", publisher = "Nature", journal = "Gene Therapy", title = "TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer", volume = "17", number = "4", pages = "550-559", doi = "10.1038/gt.2010.5" }
Ziauddin, M.F., Guo, Z.S., O'Malley, M.E., Austin, F., Popović, P., Kavanagh, M.A., Li, J., Sathaiah, M., Thirunavukarasu, P., Fang, B., Lee, Y.J.,& Bartlett, D.L.. (2010). TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. in Gene Therapy Nature., 17(4), 550-559. https://doi.org/10.1038/gt.2010.5
Ziauddin M, Guo Z, O'Malley M, Austin F, Popović P, Kavanagh M, Li J, Sathaiah M, Thirunavukarasu P, Fang B, Lee Y, Bartlett D. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. in Gene Therapy. 2010;17(4):550-559. doi:10.1038/gt.2010.5 .
Ziauddin, M.F., Guo, Z.S., O'Malley, M.E., Austin, F., Popović, Petar, Kavanagh, M.A., Li, J., Sathaiah, M., Thirunavukarasu, P., Fang, B., Lee, Y.J., Bartlett, D.L., "TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer" in Gene Therapy, 17, no. 4 (2010):550-559, https://doi.org/10.1038/gt.2010.5 . .